p300/CBP

p300/CBP製品

  • All (18)
  • p300/CBP阻害剤 (14)
  • p300/CBP活性剤(1)
  • p300/CBPモジュレータ(3)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S2662 ICG-001 ICG-001 antagonizes Wnt/β-catenin/TCF-mediated transcription and specifically binds to CREB-binding protein (CBP) with IC50 of 3 μM, but is not the related transcriptional coactivator p300. ICG-001 induces apoptosis.
Cancer Discov, 2025, 10.1158/2159-8290.CD-25-0629
Adv Sci (Weinh), 2025, 12(40):e05702
Cell Rep Med, 2025, 6(2):101927
ICG-001-S2662W0120141110.gif
S7152 C646 C646 is an inhibitor for histone acetyltransferase, and inhibits p300 with a Ki of 400 nM in a cell-free assay. Preferentially selective for p300 versus other acetyltransferases. C646 induces cell cycle arrest, apoptosis and autophagy.
Nat Commun, 2025, 16(1):4502
Nat Commun, 2025, 16(1):524
J Extracell Vesicles, 2025, 14(2):e70042
C646-S715201W0420170215.gif
S1848 Curcumin Curcumin (Diferuloylmethane, Natural Yellow 3, Turmeric yellow) is the principal curcuminoid of the popular Indian spice turmeric, which is a member of the ginger family (Zingiberaceae). It is an inhibitor of p300 histone acetylatransferase(IC50~25 μM)and Histone deacetylase (HDAC); activates Nrf2 pathway and supresses the activation of NF-κB. Curcumin induces mitophagy, autophagy, apoptosis, and cell cycle arrest with antitumor activity. Curcumin reduces renal damage associated with rhabdomyolysis by decreasing ferroptosis-mediated cell death. Curcumin exhibits anti-infective properties against various human pathogens like the influenza virus, hepatitis C virus, HIV and so on.
J Biol Chem, 2025, 301(7):110305
Mol Pain, 2025, 21:17448069251323668
BMC Immunol, 2025, 26(1):67
Curcumin-S184801W0220140528.gif
S7256 SGC-CBP30 SGC-CBP30 is a potent CREBBP/EP300 inhibitor with IC50 of 21 nM and 38 nM in cell-free assays, respectively. Exhibits 40-fold and 250-fold selectivity for CBP over the first BRD of BRD4 (BRD4(1)) and BRD4(2) respectively.
Mol Cell, 2025, 85(8):1525-1542.e10
Cell Death Dis, 2025, 16(1):193
Cell Rep, 2025, 44(4):115523
SGC-CBP30-S725601W0220181210.gif
S8968 PRI-724 (Foscenvivint) Foscenvivint (PRI-724) is a potent and specific inhibitor that disrupts the interaction of β-catenin and CBP.
Cancer Discov, 2025, 10.1158/2159-8290.CD-25-0629
Cell Death Dis, 2025, 16(1):466
Biomed Pharmacother, 2025, 188:118225
S8740 A-485 A-485 is a potent, selective and drug-like p300/CBP catalytic inhibitor with an IC50 of 0.06 μM for p300 HAT. It is selective over BET bromodomain proteins and >150 non-epigenetic targets.
Nat Genet, 2025, 57(10):2468-2481
Cancer Discov, 2025, 15(2):382-400
Nat Cell Biol, 2025, 10.1038/s41556-025-01658-1
S9648 NEO2734 (EP31670) NEO2734 (EP31670) is a novel, orally active and selective dual inhibitor of p300/CBP and BET bromodomain with IC50 of both <30 nM.
Cell Rep Med, 2024, 5(3):101471
Nat Cancer, 2023, 4(10):1508-1525
PLoS Pathog, 2023, 19(8):e1011598
S8190 CPI-637 CPI-637 is a selective and cell-active benzodiazepinone CBP/EP300 bromodomain inhibitor.
Mol Cell Proteomics, 2023, 22(3):100504
Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0237-5
S6758 I-CBP112 I-CBP112 is a potent and selective CBP/p300 inhibitor with dissociation constant (KD) of 151 ± 6 nM and 167 ± 8 nM for CBP and p300, respectively.
Hepatology, 2021, 10.1002/hep.32245
Hepatology, 2021, 10.1002/hep.32245
S0022 YF-2 YF-2 is a highly selective, blood-brain-barrier permeable activator of histone acetyltransferase (HAT). In In vitro assays, YF-2 has activity versus CBP, PCAF, and GCN5 with EC50 of 2.75 μΜ, 29.04 μΜ and 49.3 μΜ, respectively. YF-2 also increases p300 activity.
J Extracell Vesicles, 2025, 14(2):e70042
J Exp Clin Cancer Res, 2022, 41(1):77
S1161 Histone Acetyltransferase Inhibitor II

Histone Acetyltransferase Inhibitor II (HAT Inhibitor II, compound 2c) is a potent, selective and cell-permeable p300 histone acetyltransferase (HAT) inhibitor with IC50 of 5 μM. Histone Acetyltransferase Inhibitor II shows anti-acetylase activity in mammalian cells.

Genetics, 2017, 205(3):1125-1137
S3984 Nordihydroguaiaretic acid (NDGA) Nordihydroguaiaretic acid (NDGA) is a phenolic antioxidant found in the leaves and twigs of the evergreen desert shrub, Larrea tridentata (Sesse and Moc. ex DC) Coville (creosote bush). It is a recognized inhibitor of lipoxygenase (LOX) and has antioxidant and free radical scavenging properties. Nordihydroguaiaretic acid (NDGA) is a cytotoxic insulin-like growth factor-I receptor (IGF-1R)/HER2 inhibitor and induces apoptosis. Nordihydroguaiaretic acid (NDGA) inhibits p300 and activates autophagy. Nordihydroguaiaretic acid (NDGA) protects cells from ferroptosis.
Gut Microbes, 2025, 17(1):2518338
S8625 GNE-049 GNE-049 is a highly potent and selective inhibitor of CBP. It exhibits an IC50 of 1.1 nM in TR-FRET assay. GNE-049 also effectively inhibits BRET and BRD4 with IC50 values of 12 nM and 4200 nM, respectively.
Nat Genet, 2025, 57(10):2468-2481
S7582 Anacardic Acid Anacardic Acid (6-pentadecylsalicylic Acid) is a potent inhibitor of p300 and p300/CBP-associated factor histone acetyltranferases, which also has antibacterial activity, antimicrobial activity, prostaglandin synthase inhibition, and tyrosinase and lipoxygenase inhibition.
Sci Adv, 2025, 11(9):eadq2881
J Transl Med, 2024, 22(1):995
Int J Mol Sci, 2024, 25(17)9600
Anacardic-Acid-S758201W0220170527.gif
S6876 CPI-1612 CPI-1612 is a highly potent, orally active inhibitor of EP300/CBP histone acetyltransferase (HAT). It displays an IC50 of 8.0 nM for EP300 HAT. CPI-1612 suppresses H3K27 acetylation in vivo and exhibits efficacy in JEKO-1 mantle cell lymphoma xenograft at a low dose. CPI-1612 displays anticancer activity.
E1348 E7386 E-7386 is a selective inhibitor which inhibits interaction between CBP/beta-catenin with IC50 value of 0.0484 μM in HEK293 cells.
Adv Sci (Weinh), 2024, 11(35):e2308417
Cell Rep, 2024, 43(8):114532
S9667 Inobrodib (CCS-1477) Inobrodib (CCS1477; CBP-IN-1; CBP/p300-IN-4)is a potent and selective inhibitor of p300/CBP bromodomain. CCS1477 works by inhibiting the expression and function of the androgen receptor (AR), as well as inhibiting c-Myc.
Nat Genet, 2025, 57(10):2468-2481
Nat Commun, 2025, 16(1):4133
PLoS Pathog, 2025, 21(9):e1013073
S2966 TTK21 TTK21 is an activator of the histone acetyltransferases CBP/p300. It activates CBP/p300 histone acetyltransferase activity in a concentration-dependent manner with a maximal effect at a concentration of 275 µM. TTK21 passes the blood–brain barrier, induces no toxicity, and reaches different brain parts when conjugated to glucose-based carbon nanosphere (CSP).
Chin Med J (Engl), 2025, 10.1097/CM9.0000000000003567
S7152 C646 C646 is an inhibitor for histone acetyltransferase, and inhibits p300 with a Ki of 400 nM in a cell-free assay. Preferentially selective for p300 versus other acetyltransferases. C646 induces cell cycle arrest, apoptosis and autophagy.
Nat Commun, 2025, 16(1):4502
Nat Commun, 2025, 16(1):524
J Extracell Vesicles, 2025, 14(2):e70042
C646-S715201W0420170215.gif
S1848 Curcumin Curcumin (Diferuloylmethane, Natural Yellow 3, Turmeric yellow) is the principal curcuminoid of the popular Indian spice turmeric, which is a member of the ginger family (Zingiberaceae). It is an inhibitor of p300 histone acetylatransferase(IC50~25 μM)and Histone deacetylase (HDAC); activates Nrf2 pathway and supresses the activation of NF-κB. Curcumin induces mitophagy, autophagy, apoptosis, and cell cycle arrest with antitumor activity. Curcumin reduces renal damage associated with rhabdomyolysis by decreasing ferroptosis-mediated cell death. Curcumin exhibits anti-infective properties against various human pathogens like the influenza virus, hepatitis C virus, HIV and so on.
J Biol Chem, 2025, 301(7):110305
Mol Pain, 2025, 21:17448069251323668
BMC Immunol, 2025, 26(1):67
Curcumin-S184801W0220140528.gif
S7256 SGC-CBP30 SGC-CBP30 is a potent CREBBP/EP300 inhibitor with IC50 of 21 nM and 38 nM in cell-free assays, respectively. Exhibits 40-fold and 250-fold selectivity for CBP over the first BRD of BRD4 (BRD4(1)) and BRD4(2) respectively.
Mol Cell, 2025, 85(8):1525-1542.e10
Cell Death Dis, 2025, 16(1):193
Cell Rep, 2025, 44(4):115523
SGC-CBP30-S725601W0220181210.gif
S8740 A-485 A-485 is a potent, selective and drug-like p300/CBP catalytic inhibitor with an IC50 of 0.06 μM for p300 HAT. It is selective over BET bromodomain proteins and >150 non-epigenetic targets.
Nat Genet, 2025, 57(10):2468-2481
Cancer Discov, 2025, 15(2):382-400
Nat Cell Biol, 2025, 10.1038/s41556-025-01658-1
S9648 NEO2734 (EP31670) NEO2734 (EP31670) is a novel, orally active and selective dual inhibitor of p300/CBP and BET bromodomain with IC50 of both <30 nM.
Cell Rep Med, 2024, 5(3):101471
Nat Cancer, 2023, 4(10):1508-1525
PLoS Pathog, 2023, 19(8):e1011598
S8190 CPI-637 CPI-637 is a selective and cell-active benzodiazepinone CBP/EP300 bromodomain inhibitor.
Mol Cell Proteomics, 2023, 22(3):100504
Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0237-5
S6758 I-CBP112 I-CBP112 is a potent and selective CBP/p300 inhibitor with dissociation constant (KD) of 151 ± 6 nM and 167 ± 8 nM for CBP and p300, respectively.
Hepatology, 2021, 10.1002/hep.32245
Hepatology, 2021, 10.1002/hep.32245
S1161 Histone Acetyltransferase Inhibitor II

Histone Acetyltransferase Inhibitor II (HAT Inhibitor II, compound 2c) is a potent, selective and cell-permeable p300 histone acetyltransferase (HAT) inhibitor with IC50 of 5 μM. Histone Acetyltransferase Inhibitor II shows anti-acetylase activity in mammalian cells.

Genetics, 2017, 205(3):1125-1137
S3984 Nordihydroguaiaretic acid (NDGA) Nordihydroguaiaretic acid (NDGA) is a phenolic antioxidant found in the leaves and twigs of the evergreen desert shrub, Larrea tridentata (Sesse and Moc. ex DC) Coville (creosote bush). It is a recognized inhibitor of lipoxygenase (LOX) and has antioxidant and free radical scavenging properties. Nordihydroguaiaretic acid (NDGA) is a cytotoxic insulin-like growth factor-I receptor (IGF-1R)/HER2 inhibitor and induces apoptosis. Nordihydroguaiaretic acid (NDGA) inhibits p300 and activates autophagy. Nordihydroguaiaretic acid (NDGA) protects cells from ferroptosis.
Gut Microbes, 2025, 17(1):2518338
S8625 GNE-049 GNE-049 is a highly potent and selective inhibitor of CBP. It exhibits an IC50 of 1.1 nM in TR-FRET assay. GNE-049 also effectively inhibits BRET and BRD4 with IC50 values of 12 nM and 4200 nM, respectively.
Nat Genet, 2025, 57(10):2468-2481
S7582 Anacardic Acid Anacardic Acid (6-pentadecylsalicylic Acid) is a potent inhibitor of p300 and p300/CBP-associated factor histone acetyltranferases, which also has antibacterial activity, antimicrobial activity, prostaglandin synthase inhibition, and tyrosinase and lipoxygenase inhibition.
Sci Adv, 2025, 11(9):eadq2881
J Transl Med, 2024, 22(1):995
Int J Mol Sci, 2024, 25(17)9600
Anacardic-Acid-S758201W0220170527.gif
S6876 CPI-1612 CPI-1612 is a highly potent, orally active inhibitor of EP300/CBP histone acetyltransferase (HAT). It displays an IC50 of 8.0 nM for EP300 HAT. CPI-1612 suppresses H3K27 acetylation in vivo and exhibits efficacy in JEKO-1 mantle cell lymphoma xenograft at a low dose. CPI-1612 displays anticancer activity.
E1348 E7386 E-7386 is a selective inhibitor which inhibits interaction between CBP/beta-catenin with IC50 value of 0.0484 μM in HEK293 cells.
Adv Sci (Weinh), 2024, 11(35):e2308417
Cell Rep, 2024, 43(8):114532
S9667 Inobrodib (CCS-1477) Inobrodib (CCS1477; CBP-IN-1; CBP/p300-IN-4)is a potent and selective inhibitor of p300/CBP bromodomain. CCS1477 works by inhibiting the expression and function of the androgen receptor (AR), as well as inhibiting c-Myc.
Nat Genet, 2025, 57(10):2468-2481
Nat Commun, 2025, 16(1):4133
PLoS Pathog, 2025, 21(9):e1013073
S2966 TTK21 TTK21 is an activator of the histone acetyltransferases CBP/p300. It activates CBP/p300 histone acetyltransferase activity in a concentration-dependent manner with a maximal effect at a concentration of 275 µM. TTK21 passes the blood–brain barrier, induces no toxicity, and reaches different brain parts when conjugated to glucose-based carbon nanosphere (CSP).
Chin Med J (Engl), 2025, 10.1097/CM9.0000000000003567
S2662 ICG-001 ICG-001 antagonizes Wnt/β-catenin/TCF-mediated transcription and specifically binds to CREB-binding protein (CBP) with IC50 of 3 μM, but is not the related transcriptional coactivator p300. ICG-001 induces apoptosis.
Cancer Discov, 2025, 10.1158/2159-8290.CD-25-0629
Adv Sci (Weinh), 2025, 12(40):e05702
Cell Rep Med, 2025, 6(2):101927
ICG-001-S2662W0120141110.gif
S8968 PRI-724 (Foscenvivint) Foscenvivint (PRI-724) is a potent and specific inhibitor that disrupts the interaction of β-catenin and CBP.
Cancer Discov, 2025, 10.1158/2159-8290.CD-25-0629
Cell Death Dis, 2025, 16(1):466
Biomed Pharmacother, 2025, 188:118225
S0022 YF-2 YF-2 is a highly selective, blood-brain-barrier permeable activator of histone acetyltransferase (HAT). In In vitro assays, YF-2 has activity versus CBP, PCAF, and GCN5 with EC50 of 2.75 μΜ, 29.04 μΜ and 49.3 μΜ, respectively. YF-2 also increases p300 activity.
J Extracell Vesicles, 2025, 14(2):e70042
J Exp Clin Cancer Res, 2022, 41(1):77